{"id":796923,"date":"2024-12-24T09:33:09","date_gmt":"2024-12-24T14:33:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/"},"modified":"2024-12-24T09:33:09","modified_gmt":"2024-12-24T14:33:09","slug":"achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/","title":{"rendered":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">&#8211; Proprietary data and samples from TRACERx and Achilles\u2019 Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction &#8211;<\/p>\n<p align=\"center\">&#8211; Conclusion of Strategic Review &#8211;<\/p>\n<p align=\"justify\">LONDON, Dec.  24, 2024  (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx\u00ae Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (LSE\/STO\/Nasdaq: AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by\u00a0Professor Charles Swanton\u00a0at\u00a0University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over as sponsor of Achilles\u2019 Material Acquisition Platform (MAP), and receive tumor samples and data collected thus far. MAP is a proprietary network that has collected donor tumor tissue and blood from nearly 300 cancer patients undergoing standard-of-care cancer surgery across multiple solid tumor indications, including lung, melanoma, head and neck, renal, bladder, and breast.<\/p>\n<p align=\"justify\">\u201cWe are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets,\u201d said Dr Iraj Ali, CEO of Achilles Therapeutics. \u201cWe believe that these assets have the potential to positively impact Oncology R&amp;D and will support the development of new and improved therapies for cancer patients.\u201d<\/p>\n<p align=\"justify\">AstraZeneca has agreed to pay Achilles Therapeutics $12M for the assets in total.<\/p>\n<p align=\"justify\">BofA Securities provided strategic financial advice to Achilles for the transaction. Completion of this transaction signals the conclusion of Achilles\u2019 strategic review which was announced in September 2024. Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors, while remaining compliant with Nasdaq and SEC requirements.<\/p>\n<p>\n        <strong>About Achilles Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Achilles is a clinical-stage biopharmaceutical company that has been developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles has used DNA sequencing data from each patient, together with its proprietary PELEUS<sup>TM<\/sup> bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.<\/p>\n<p>\n        <strong>About TRACERx<\/strong>\n      <\/p>\n<p align=\"justify\">TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by\u00a0Professor Charles Swanton\u00a0at\u00a0UCL, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. TRACERx has transformed the understanding of tumor evolution and has convincingly shown that tumors originate from a single cell that evolves in a Darwinian manner and the early (clonal) mutations are preserved in all subsequent primary and metastatic tumor cells. The study, which has generated numerous publications, uncovered important mechanisms of cancer evolution and immune evasion by analyzing genetic signatures in lung tumors and tracking how they evolve over time from diagnosis through to relapse. These findings provide the ability to identify a novel class of tumor markers called clonal neoantigens that are present on all tumor cells yet absent from healthy tissue, making them ideal cancer targets. TRACERx represents the largest investment in lung cancer research by\u00a0Cancer Research UK.\u00a0<\/p>\n<p>\n        <strong>Forward Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains express or implied forward-looking statements that are based on the Company management&#8217;s belief and assumptions and on information currently available to the Company\u2019s management. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company\u2019s clinical trials and the Company\u2019s beliefs about its goals for the discontinued trials; expectations related to the Company\u2019s cash runway and operating expenses and capital expense requirements; the Company\u2019s ability to engage with third parties who are developing alternative modalities to target clonal neoantigens for the treatment of cancers and the Company\u2019s review and evaluation of potential strategic options and their impact on stockholder value. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or the Company\u2019s future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent the Company\u2019s views as of the date of this press release. We anticipate that subsequent events and developments will cause the Company\u2019s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing the Company\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p align=\"justify\">For further information, please contact:<\/p>\n<p>\n        <strong>Meru Advisors<\/strong><br \/>\n        <br \/>\n        <strong>Lee M. Stern<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mSod1BleyFG9Nah2i6Rk2mKmeiBsyeCtDSrA96euKLnBz-GSi9533G5NHI56JDarU4xizY7l-LSpLpI2oR2AqsPnjmE32Xkv6sffBIW0a-g=\" rel=\"nofollow\" target=\"_blank\">lstern@meruadvisors.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGE0ZGFkZTctNWU5OS00MjViLWJiYzAtNzEyZmVjNGU0ZTdlLTEyMTgyOTg=\/tiny\/Achilles-Therapeutics-PLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Proprietary data and samples from TRACERx and Achilles\u2019 Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction &#8211; &#8211; Conclusion of Strategic Review &#8211; LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx\u00ae Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (LSE\/STO\/Nasdaq: AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by\u00a0Professor Charles Swanton\u00a0at\u00a0University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-796923","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Proprietary data and samples from TRACERx and Achilles\u2019 Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction &#8211; &#8211; Conclusion of Strategic Review &#8211; LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx\u00ae Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (LSE\/STO\/Nasdaq: AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by\u00a0Professor Charles Swanton\u00a0at\u00a0University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over as &hellip; Continue reading &quot;Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-24T14:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca\",\"datePublished\":\"2024-12-24T14:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/\"},\"wordCount\":844,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/\",\"name\":\"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=\",\"datePublished\":\"2024-12-24T14:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Market Newsdesk","og_description":"&#8211; Proprietary data and samples from TRACERx and Achilles\u2019 Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction &#8211; &#8211; Conclusion of Strategic Review &#8211; LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx\u00ae Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (LSE\/STO\/Nasdaq: AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by\u00a0Professor Charles Swanton\u00a0at\u00a0University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over as &hellip; Continue reading \"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-24T14:33:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca","datePublished":"2024-12-24T14:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/"},"wordCount":844,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/","name":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=","datePublished":"2024-12-24T14:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMzM3NiM2NjQ3NTIzIzIyMDY3NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/796923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=796923"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/796923\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=796923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=796923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=796923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}